Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Conditions
Interventions
bb2121
Daratumumab
+7 more
Locations
60
United States
Local Institution - 109
Birmingham, Alabama, United States
Local Institution - 141
Scottsdale, Arizona, United States
Local Institution - 145
Los Angeles, California, United States
Local Institution - 122
Los Angeles, California, United States
Local Institution - 124
Palo Alto, California, United States
Local Institution - 142
Aurora, Colorado, United States
Start Date
April 16, 2019
Primary Completion Date
April 8, 2027
Completion Date
April 8, 2027
Last Updated
December 15, 2022
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions